KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Royalty Pharma (RPRX) over the last 6 years, with Q3 2025 value amounting to $3.1 million.

  • Royalty Pharma's Other Accumulated Expenses fell 8999.68% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 8999.68%. This contributed to the annual value of $68.6 million for FY2024, which is 50307.69% up from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Other Accumulated Expenses is $3.1 million, which was down 8999.68% from $3.1 million recorded in Q2 2025.
  • Royalty Pharma's 5-year Other Accumulated Expenses high stood at $97.5 million for Q2 2024, and its period low was $3.1 million during Q2 2025.
  • For the 5-year period, Royalty Pharma's Other Accumulated Expenses averaged around $25.9 million, with its median value being $11.9 million (2022).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 50307.69% in 2024, then crashed by 9684.59% in 2025.
  • Over the past 5 years, Royalty Pharma's Other Accumulated Expenses (Quarter) stood at $4.3 million in 2021, then skyrocketed by 187.44% to $12.4 million in 2022, then dropped by 8.27% to $11.4 million in 2023, then soared by 503.08% to $68.6 million in 2024, then crashed by 95.45% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $3.1 million for Q2 2025, and $18.6 million during Q1 2025.